Metronidazol B. Braun (Metronidazole)

Metronidazole is taken up by anaerobic microorganisms and reduced to reactive nitro radicals. These radicals damage DNA and inhibit nucleic acid synthesis, leading to cell death. The selective reduction occurs mainly in anaerobic cells, sparing most aerobic human tissues.

The specific dose and infusion rate are determined by the prescribing clinician based on the infection type, severity, patient weight, renal and hepatic function, and local treatment guidelines. Healthcare professionals should follow the recommended dosing regimen on the product label or institutional protocol.

Safety data are limited; metronidazole is generally classified as a drug to be used in pregnancy only when the potential benefit justifies the potential risk to the fetus. It is excreted in breast milk, so breastfeeding mothers should consult their physician before use.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Metronidazole is a first‑line nitroimidazole with broad activity against anaerobes and certain protozoa. Alternatives such as clindamycin or carbapenems may be used when resistance or intolerance to metronidazole occurs. Compared with tinidazole, metronidazole has a longer clinical history and more extensive safety data, though tinidazole offers a longer half‑life allowing less frequent dosing.

The product should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Before administration, allow the solution to reach room temperature if required, and inspect for particulate matter or discoloration.

Metronidazol B. Braun is administered intravenously by slow infusion under aseptic conditions. The infusion rate and total daily dose are set by the treating physician, and the medication may be given as a single daily dose or divided doses depending on the clinical scenario.

Serious adverse events include seizures, peripheral neuropathy, severe allergic reactions such as anaphylaxis, and rare skin disorders like Stevens‑Johnson syndrome. Patients should be monitored for neurological symptoms, rash, or signs of hypersensitivity, and therapy should be discontinued if any of these occur.

Metronidazol B. Braun is contraindicated in patients with a known hypersensitivity to metronidazole or other nitroimidazoles. Caution is also advised for individuals with severe hepatic impairment, those receiving disulfiram, or patients with a history of seizures or peripheral neuropathy, unless the benefits outweigh the risks.